mRNA Vaccine Technology: Molecular Design, Delivery Systems, Immunological Mechanisms, Clinical Applications, and Future Perspectives

Authors – Amandeep Kandari, Saidmurodova Malikabonu Baxtiyorovna, Sneha Jha

Abstract

mRNA vaccines have become an important advancement in the current world of vaccinology. These vaccines use synthetic mRNA to deliver genetic information into cells, instructing the cells to temporarily produce specific antigens, leading to antigen specific immune responses. The clinical significance of vaccine technology has been shown with the development of mRNA vaccines for the treatment of COVID-19. Within a short time frame mRNA vaccines have been developed from experimental to a widely used medical treatment, due to significant research into RNA modifications, molecular engineering, innate immune responses, and lipid nano-particle delivery systems.

This article discusses how mRNA vaccines have been developed. Key areas such as molecular design, RNA synthesis, antigen design, lipid nano-particle formulation, cellular delivery and immune responses will be discussed. The differences between conventional non-replicating, self-amplifying and circular mRNA vaccines will be discussed. Clinical applications of the vaccines will be covered including infectious diseases and immunotherapy. Evidence from randomized clinical trials and neo-antigen vaccines will be reviewed. Limitations to the vaccines such as formulation, endosomal escape, innate immune responses, reactogenicity, complexity and availability will be critically reviewed. New developments such as advanced lipid chemistry, targeted cell delivery, computer based antigen selection and optimal RNA designs will be discussed. Despite the clinical applications of mRNA vaccines, the overall therapeutic potential of these vaccines will depend on disease validation, improved formulation and continued evaluation.

Keywords:

messenger RNA, mRNA vaccines, lipid nano-particles, vaccine biotechnology, molecular engineering, antigen presentation, adaptive immunity, self-amplifying RNA, circular RNA, cancer immunotherapy.

1. Introduction

Vaccination has drastically changed how infectious diseases are prevented. Traditional vaccine development has focused on attenuated microbes, inactivated pathogens, recombinant proteins, polysaccharides and viral vectors. This has helped control many infectious diseases. However, with new pathogens appearing and evolving, vaccine development has become very important to be able to quickly adapt and react.

1.1 mRNA Vaccines

The genetic information needed to create the antigen is separated. It means that instead of producing and delivering the protein, researchers produce a synthetic RNA molecule with the genetic information needed to produce the protein inside the host cell.

Many years ago the foundations of this vaccine technology were laid. In the early 1990s experiments showed that synthetic mRNA delivered externally can cause protein production in living organisms. This proved that nucleic acid vaccines could be used but there were many issues with the RNA such as instability and poor delivery.[1,2]

As research continued improvements were made to overcome many of these problems. It was discovered that adding modified nucleosides to the RNA would change how it interacts with innate immune responses of the host. Improvements were also made to the purity, optimization and lipid delivery of the RNA.

The development of the **BNT162b2** and **mRNA-1273** vaccines for severe acute respiratory syndrome. Coronavirus 2 (SARS-CoV-2) were a key part of this development. Randomized phase III clinical trials demonstrated that they had great potency against symptomatic cases of COVID-19.[5,6]

However, the vaccine technology has been important in more ways than just with the development of vaccines for the prevention of COVID-19. As they are modular, they can be used to create vaccines for other infectious diseases as well as therapeutics using tumour associated antigens. Research is now being done on self-amplifying and circular RNA vaccines, as well as delivery to specific tissues.

2. History and Development

mRNA vaccines have developed as a result of research in many areas. Molecular genetics, immunology, cell biology and pharmaceutical engineering.

A key development was discovering that delivering mRNA directly could cause the production of active proteins within animal tissue. In 1990 Wolff and colleagues demonstrated that nucleic acids could be delivered by injection to cause protein expression in skeletal muscle.[1]

However, the RNA was unstable and caused little interest. Compared to DNA, RNA is more susceptible to degradation. Due to its large size and negative charge it is difficult to deliver into cells.

A huge development occurred when looking at how synthetic RNA would interact with innate immune receptors. It was discovered that adding naturally occurring modified nucleosides to the RNA could greatly reduce the inflammatory response caused by synthetic RNA[3]. This helped demonstrate how important the nucleotide composition was in therapeutic RNA.

Efficient lipid delivery systems were developed. It helped protect the RNA from degradation outside of the cell and aid delivery to the inside of cells. Eventually it led to clinically successful mRNA vaccines. [4]

Due to the fast response to SARS-CoV-2 much knowledge was gained. When the genetic sequence was known the antigen could be designed without needing to develop a traditional method of producing the pathogen. Despite needing to be tested in clinical trials, validated in manufacturing and assessed by regulatory bodies the antigen could be designed much quicker than many traditional methods.

The clinical success of mRNA vaccines was due to the lengthy development.

3. Molecular Design of Conventional mRNA Vaccines

The performance of an mRNA vaccine will depend on the molecular design. Conventional non-replicating mRNA vaccines consist of many different areas.

3.1 5’ Cap

A modified guanosine molecule is added to the start of the molecule. This helps protect mRNA from degradation by certain exonucleases.

They are important in eukaryotic cells as they can help recruit ribosomal machinery. The cap can affect how effectively translation occurs.

Appropriate methods of capping should be used to create synthetic mRNA.

3.2 5’ and 3’ Untranslated Regions

These contain sequences that are not coding for the protein. They have many important functions.

The 5’ UTR helps recruit ribosomes to translate. The nucleotides and structure can affect how easily this can occur.

The 3’ UTR helps with stability of the RNA. Different sequences can cause different levels of protein to be expressed.

Choosing the correct UTR is an important part of optimizing mRNA. The best sequence will depend on the application and the balance between efficiency and stability.[7]

3.3 Coding Region and Antigen Design

This is where the information to create the antigen can be found.

For a vaccine against a virus, this may contain information to create a glycoprotein on the surface of the virus or any protein associated to the pathogen that can cause an immune response.

When designing antigens researchers must consider how the protein will fold, whether it will be stable or not and how accessible the antigen will be. They should also ensure that the correct epitopes are present for immune responses.

When designing SARS-CoV-2 mRNA vaccines, the spike protein was stabilised to create a prefusion version. This was important as it contained antigenic features.[5,6]

Codon optimization can be performed to alter translation. However this is not always beneficial as it can change the structure of the RNA.

3.4 Poly(A)

The poly-adenylated sequence is found at the end of conventional mRNA. It interacts with proteins inside the cell to help with translation.

The length and structure can affect how effective the translation is. However this is not always the case as too much or inappropriate changes can affect performance.

3.5 Nucleoside Modifications

Synthetic RNA can be created with modifications to the nucleosides to alter immune responses and protein expression.

Pseudouridine derivatives (specifically N1-methylpseudouridine) have been a big development in this area.

Modifications can help reduce recognition by certain innate immune responses. They can also improve translation in some synthetic RNA. However different modifications will have different effects and depend on the vaccine formulation and required immune response.[3,7]

Overall all parts of the mRNA will interact with each other to create the correct amount, location and length of antigen expression.

4. Production of mRNA Vaccines

mRNA vaccines are created differently compared to traditional protein based vaccines. They are generally produced using an enzyme based, cell free method.

First a DNA template containing the required antigen and regulatory sequences will be created. It is then used in an in-vitro transcription reaction with the RNA polymerase creating the correct RNA.

4.1 In-Vitro Transcription

This is a key step in creating conventional synthetic mRNA.

The reaction requires a DNA template, RNA polymerase, nucleotide triphosphates and appropriate conditions. The RNA should contain the correct sequence and structure.

However unwanted products can be formed such as incomplete transcripts and double stranded RNA. This is important as it can affect innate immune activation.

4.2 RNA Purification

The RNA will need to be purified to remove any remaining DNA, enzymes, free nucleotides and unwanted RNA.

Depending on the platform different methods can be used.

It is important to analyze the RNA to ensure there are no double stranded RNAs, incomplete transcripts or other impurities.

4.3 Formulation

The purified mRNA will be formulated with an appropriate delivery system. Most often this will be lipid nano-particles.

During formulation the particles should have consistent characteristics such as particle size, RNA encapsulation, lipid composition and stability.

4.4 Quality Control

There are many factors to consider when determining the quality of the final product.

- RNA sequence, concentration and purity.
- Cap and poly(A).
- Encapsulation.
- Lipid composition and particle size.
- DNA contamination.
- Potency.
- Sterility and endotoxins.
- Stability.

As mRNA products are sensitive to formulation and changes in the process, it is important to ensure a consistent product.

5. Lipid Nano-particle Delivery

One of the biggest challenges when developing RNA based vaccines is delivering synthetic mRNA into cells.

RNA is negatively charged so cannot easily penetrate the hydrophobic cell membrane. It is also sensitive to ribo-nucleases in the extracellular environment.

Lipid nano-particles can help protect the RNA and deliver it into cells. This has been key to allowing mRNA vaccines to be translated to the clinic.[8,9]

5.1 Key Components

Conventional lipid nano-particles will generally contain 4 key lipid components.

Ionisable lipids – Help with RNA encapsulation during formulation. Contain charges that change depending on the pH. This can affect how they interact with RNA and endosomes.

Phospholipids – Help with organization of the nanoparticle. Influence interactions with biological membranes.

Cholesterol – Helps control particle structure and lipid packing.

PEGylated lipids – Contain PEG groups. This can affect particle size, aggregation and interactions with biological systems.

The ratio and characteristics of the components will affect the particle.

5.2 Cellular Uptake

Once delivered the lipid nano-particles will interact with cells. They may be taken up using endocytosis.

The particles will be trapped in endosomes. However this does not necessarily mean the RNA will be delivered to the cytoplasm.

A proportion of RNA must escape the endosomes to allow translation. If they do not escape they will be degraded or sent to lysosomal pathways.

Endosomal escape is a key limitation of RNA delivery. Improving this may increase antigen expression without increasing the amount of RNA delivered.

5.3 Biodistribution

The composition of the lipid nano-particle will affect where the delivered material goes and what cells it interacts with.

Particle size, lipid composition, delivery route, protein interactions and physiological factors will affect biodistribution.

When developing vaccines it is important to consider how the delivery systems will interact with antigen presenting cells. However it is not always accurate to assume all particles will interact with dendritic cells. Antigen expression can occur in many different cell types and this will lead to antigen uptake and presentation to create an immune response. Future formulations may improve targeting to specific tissues/immune cells by modifying the lipids and adding targeting ligands.[8,9]

6. Immune Responses to mRNA Vaccines

The protection caused by mRNA vaccines comes from the interaction between antigen production, innate immune responses and adaptive immune responses.

Unlike traditional vaccines, mRNA vaccines cause the recipient to produce the chosen protein using their cells. This can allow the antigens to be processed.

6.1 Innate Immune Response

The innate immune system recognizes molecular patterns associated with infection and disruption.

Synthetic RNA can interact with many innate immune sensors such as toll like receptors and cytosolic RNA sensing.

This can cause them to activate inflammatory mediators. This can help activate antigen presenting cells.

This can be a complex area. Appropriate activation of innate immune responses can help adaptive immune responses develop. However if too much activation occurs it may cause inhibition of translation or unwanted inflammatory effects.

Therefore it is important to control innate immune stimulation during vaccine design.

6.2 MHC Class I Antigen Presentation

Antigens produced inside cells can be broken down into peptides.

Some of these peptides will be transported and presented using MHC class I (MHC-I).

CD8+ T lymphocytes recognize these peptide-MHC complexes. They can then differentiate into cytotoxic effector cells to kill cells containing the antigen.

This is an important pathway for cellular immunity. This can help fight intracellular pathogens and malignant cells.

6.3 MHC Class II Antigen Presentation

Extracellular antigens and antigens from other cells can be taken up by professional antigen presenting cells such as dendritic cells.

Once processed, antigen derived peptides can be presented using MHC class II.

This activates CD4+ helper T lymphocytes. They will co-ordinate antibody responses.

6.4 B-Cell Activation

B lymphocytes recognize specific antigenic structures using receptors on their surface.

If they receive the correct signals from helper T cells they can proliferate, differentiate and mature.

Some will become plasma cells to produce antibodies. Others will become memory B cells.

Antibodies may neutralize infectious agents by stopping them attaching to cells in the body.

6.5 Immune Memory

Creating immune memory is a key aim of vaccination.

Long lived antibody producing cells (memory B cells) and memory T lymphocytes may be created following immunization.

How long these cells last and their function will depend on the antigen, vaccine formulation, immunization schedule and individual immune characteristics.

The relationship between antibody levels in circulation and long term protection will vary between pathogens. Therefore vaccine effectiveness should be determined by clinical outcomes and immunological measurements of specific diseases.[10,11]

7. Major mRNA Vaccines

Whilst the majority of clinical work has focused on conventional non-replicating mRNA, there are a number of related RNA platforms.

7.1 Conventional non-replicating mRNA

Conventional mRNA vaccines consist of an antigen coding region and regulatory elements for protein translation.

Upon entering the cytosol mRNA is translated into protein.

This is a simple design that has paved the way for the development of effective vaccines against COVID-19 and other clinical candidates.

The main benefits of conventional mRNA vaccines include the modular design and ability to easily personalize the antigen whilst maintaining a similar manufacturing platform.

7.2 Self-amplifying RNA

Self-amplifying RNA (saRNA) includes additional sequences which encode viral proteins involved in reproduction. These are usually derived from positive sense RNA viruses.

Once delivered into the cytosol the RNA is amplified using the replication machinery. This may increase the amount of antigen produced from a smaller amount of RNA.

The theory behind self-amplifying RNA is that less doses are required. However, the increased size of the RNA may cause challenges in manufacturing. The saRNA must be thoroughly investigated in relation to its effect on the innate immune response, efficiency of replication, antigen expression and safety.

There is clinical evidence for self-amplifying RNA. A phase III trial investigating an saRNA based booster for COVID-19 (ARCT-154) compared to BNT162b2 was published in The Lancet Infectious Diseases. This trial demonstrated the immunogenicity and safety of the vaccine.[12]

Self-amplifying RNA vaccines have been approved for use in Japan for the treatment of COVID-19 in 2023, demonstrating the potential for clinical development. However, the effectiveness of this platform will vary depending on the product.

7.3 Circular RNA

Circular RNA (cRNA) differs to conventional linear mRNA due to the linkage of 5' and 3' ends via covalent bonds.

This may increase resistance to certain types of exonuclease degradation.

Some circular RNAs can be translated to produce proteins via internal ribosome entry sites and other translation mechanisms.

The potential benefits of circular RNAs include the increase in stability of the molecule and increased duration of protein production. However, increased stability does not necessarily increase vaccine effectiveness.

The purity of the manufacture, contamination with unwanted linear RNA, translation efficiency, innate immune response and safety must all be thoroughly investigated. Circular RNA vaccines are still an emerging platform and therefore there is much less clinical evidence compared to conventional mRNA vaccines.[13]

7.4 Comparison of the major platforms

Characteristic	Conventional mRNA	Self-amplifying RNA	Circular RNA
Molecular structure	Linear	Linear, replication-competent	Circular
Intracellular replication	No	Yes	Not inherently
Antigen expression	Direct translation	Translation plus RNA amplification	Depends on engineered translation mechanism
Potential dose efficiency	Established	Potential dose sparing	Under investigation
Manufacturing complexity	Established processes	Additional sequence and process demands	Specialized synthesis and purification
Clinical maturity	Highest	Advancing	Early-stage

It can be seen that these vaccines all target different challenges. The advantages of each platform will depend on the disease being targeted, delivery method, manufacturing and clinical needs.

8. Clinical Application in Infectious Disease

8.1 COVID-19

The first large scale example of mRNA vaccines being used in a clinical setting was for the treatment of COVID-19. The phase III trial of BNT162b2 demonstrated ~95% efficacy against symptomatic COVID-19 in the initial analysis[5]. The phase III trial of mRNA-1273 demonstrated ~94.1% efficacy in the original trial.[6]

Result showed that an mRNA platform can provide a high level of protection against a novel viral disease. However, the changes in viral variants, immunity in the population and the time from vaccination have impacted how effective the vaccine has been.

The evidence has shown that protection against severe disease and protection against disease symptoms must be considered separately.

Overall the pandemic has proven the platform is feasible but has given us valuable insight into antigen evolution, booster vaccinations, safety and implementation of vaccines.

8.2 Respiratory Syncytial Virus

Respiratory syncytial virus (RSV) is an important cause of respiratory disease. The mRNA-1345 vaccine encodes the stabilised pre-fusion F glycoprotein which is involved in RSV entering host cells.

It was shown to be efficacious in a phase II/III clinical trial in patients aged 60 years and above.[14]

The mRNA based RSV vaccine was approved in 2024, showing that this platform can be successfully used for another respiratory disease. This shows how knowledge from the SARS-CoV-2 vaccines can be used to help design vaccines for different viruses. However, the antigen must still be specifically designed for the disease and be investigated in clinical trials.

8.3 Influenza

Influenza viruses are constantly evolving their antigen so there is a need to frequently update vaccines. The use of mRNA may provide a flexible option for developing multivalent vaccines.

Multiple antigens can be encoded which can be used to investigate the broad coverage of the vaccine. There are many factors to consider when developing an effective influenza vaccine using mRNA. These include antigen choice, immune imprinting, differences in immunity based on age and antibody responses.[10,15]

8.4 HIV

HIV is a challenging target for vaccine development. It has high genetic diversity, mutates rapidly and has ways to evade antibody mediated immunity.

A key aim when designing an HIV vaccine is to elicit broadly neutralizing antibodies which recognize conserved regions of viral envelope proteins. mRNA may allow for sequential or multi-component vaccines to be designed to deliver specific antigens. However, this will depend on overcoming the

complex immunological challenges. This area is an investigational area of clinical development and we have not yet developed an effective prophylactic mRNA vaccine.[16]

8.5 Tuberculosis and other emerging pathogens

There is increasing research into mRNA vaccines for tuberculosis and challenging pathogens. Tuberculosis is challenging to develop a vaccine for due to the complex interactions of innate immune cells and T lymphocytes to fight the bacteria living inside cells.

Vaccines for parasitic diseases and emerging viruses may require specific antigens to be chosen and delivered. The flexibility of mRNA makes it an attractive option. However, we cannot assume all pathogens will respond well to mRNA vaccines due to the success of the vaccines for COVID-19.

9. mRNA Technology in Cancer Immunotherapy

The application of mRNA technology in oncology has opened up a whole new field. Cancer vaccines aim to provoke immune responses against malignant cells. This can be achieved by delivering tumour associated antigens or tumour specific neo-antigens.

Neo-antigens are abnormal peptides generated from genetic alterations in tumour cells. These may differ to normal human proteins meaning they can be recognized by the immune system.

9.1 Personalized Neo-antigen Vaccines

Personalized cancer vaccines typically follow a few steps. Tumour tissue and a control sample are obtained from the patient. Sequencing is used to identify the mutations that are specific to the tumour.[17]

Computational techniques can be used to predict which peptides from the mutations will be presented by the patient human leukocyte antigen molecules.

The desired antigen sequences are encoded into an mRNA construct. This is manufactured and delivered using an appropriate delivery system.

This aims to provoke T lymphocytes which can recognize and attack tumour cells expressing the neo-antigens.

9.2 Pancreatic Cancer

A significant study was reported by Rojas et al in 2023. A phase I trial was performed using an personalized RNA neo-antigen vaccine (autogene cevumeran) in patients with resected pancreatic ductal adenocarcinoma.

A combination treatment of immunotherapy, personalized vaccination and chemotherapy were delivered. The researchers demonstrated T cell responses were provoked by the vaccine in a proportion of patients.

This suggests that personalized RNA vaccines can provoke tumour specific cellular immune responses. [17]

Follow-up was published in 2025 to show how long these T cell responses lasted and the link to recurrence free survival.[18]

This is promising but we cannot assume this is evidence for clinical effectiveness. These were early phase trials and the combination therapy makes it hard to determine that the results are due to the vaccine. More controlled studies are needed to demonstrate the benefit of personalized RNA neo-antigen vaccines.

9.3 Combination with Immune Checkpoint Inhibitors

Tumours can often inhibit immune responses. Immune checkpoint inhibitors such as anti-programmed death-1 and anti-programmed death ligand 1 antibodies aim to reduce some of these inhibitory signals. Combining an mRNA cancer vaccine with immune checkpoint inhibitors may have synergistic effects. The vaccine can provoke tumour specific immune responses whilst the immune checkpoint inhibitor can improve the T cell responses. However, it will depend on the tumour, antigen choice, immune cell infiltration and treatment regimen.

9.4 Challenges with Personalized Oncology

Personalized vaccines can be challenging to develop. Tumour sequencing and predicting antigens require specific techniques. The vaccine must be manufactured in a timely manner. Not all of the predicted neo-antigens will provoke T cell responses.[17,18]

Tumours can be heterogeneous meaning different malignant cells may express different antigens.

They may also develop ways to reduce antigen presentation and inhibit immune cells. Therefore, personalized mRNA vaccines should be viewed as part of an overall precision oncology strategy.

10. Safety and Reactogenicity

The success of mRNA vaccines in clinic means safety must be considered. Common side effects include: pain at injection site, fatigue, headache, fever, chills and muscular discomfort.

These are typically due to the inflammatory process caused by the vaccine. It will vary depending on the product and patient.

10.1 Innate Immune Response and Inflammation

The RNA and delivery system can impact innate immune responses. The extent of this will depend on the RNA sequence, nucleotide modifications, impurities, lipid composition, dose and route of administration.

An appropriate inflammatory response may help provoke immune responses. However, too much stimulation can reduce translation efficiency and cause unwanted systemic effects.[19]

10.2 Myocarditis and Pericarditis

Myocarditis and pericarditis have been reported as rare adverse events in certain mRNA vaccines for COVID-19. The risk varies depending on age, gender, vaccine, number of doses and surveillance method.

This requires ongoing pharmacovigilance and investigation into the biological mechanisms. We must consider what is known, what is hypothesized and the proposed mechanism.

10.3 Long Term Safety

Similar to other biologicals, the safety of an mRNA vaccine must be investigated. This includes identifying rare adverse events, risk factors, special populations and duration of adverse events. We must also consider that the biological activity of the vaccine will only last a short period of time. Conventional mRNA vaccines act in the cytosol and are not intended to integrate into the human genome.

11. Major Limitations

11.1 RNA Stability

RNA can be prone to hydrolysis and enzymatic degradation. The stability will depend on the nucleotides, sequence, storage conditions and protection offered by the delivery system.

Whilst lipid nano-particles can offer protection, it does not completely prevent degradation.

11.2 Cold Chain

Certain mRNA vaccines require storage at controlled low temperatures. This can cause issues when transporting, distributing to certain regions and delivering to areas lacking refrigeration. Improving the stability of vaccines and developing new preservation techniques are important areas of pharmaceutical research.

11.3 Poor Endosomal Escape

Even though lipid nano-particles are taken up by cells, this does not mean the mRNA will be released into the cytosol. This can cause the RNA to become trapped in endosomes and degraded. Improving delivery into cells can improve the efficiency of future vaccines and potentially reduce the dose.

11.4 Toxicity from Formulation

Lipid nano-particles can impact inflammatory signalling. The effect will depend on the chemistry of the lipid. Further investigations are needed to understand the effects of individual lipids, degradation products and repeated exposure. When looking to expand the use of this technology, it is important to thoroughly investigate the safety of the formulation.[19]

11.5 Cost of Manufacturing

Whilst the manufacturing process is modular it can be quite complex. Specialist equipment, validated manufacturing processes, analytical, trained staff and regulation are all required. This can reduce the ability to manufacture locally in low/middle income countries. Improving the infrastructure for

manufacturing in regions and making technology transfer easier will help reduce reliance on a small number of centres.

12. Future Developments

The next stage of development for mRNA vaccines will likely focus on improving the correlation between design, delivery and clinical effectiveness.

12.1 Improved Lipid Chemistry

New ionisable lipids, degradable structures and targeting agents may be used in future lipid nano-particle systems. This can improve endosomal escape, impact biodistribution and reduce unwanted inflammatory effects. Targeted delivery systems may be developed to deliver to specific tissues.

12.2 Improved Stability

Improved stability can reduce reliance on cold storage. New lipids, protective excipients and lyophilisation may provide improved pharmaceutical stability. However, stability should be investigated using appropriate analytical and biological potency methods.

12.3 Multivalent Vaccines

mRNA can be used to design vaccines with multiple antigens. This can be used to develop combination vaccines against respiratory viruses such as influenza, RSV and SARS-CoV-2. This may help simplify immunization but will need to be investigated in clinical trials to understand how the different antigens interact and provoke immune responses.

12.4 Use of Artificial Intelligence for Antigen Selection

Artificial intelligence and bioinformatics can be used to identify antigenic regions, predict protein structures and select neo-antigen candidates. This may be useful in developing personalized cancer vaccines. However, the predictions will depend on the quality of the biological data and must be validated.

12.5 Next-genration RNA Platforms

Self-amplifying and circular RNA may be used to control antigen expression and improve formulation. The potential benefits must be weighed up against the complexity of manufacturing, delivery, safety and clinical outcomes. Different RNA platforms may be more suitable for different diseases.

12.6 Global Preparedness

The pandemic has shown us that new technology must be accompanied by manufacturing, regulation and international collaboration. Investment into regional manufacturing, training, quality control and open scientific collaboration will help improve access to new vaccines.

13. Critical Discussion

Overall the development of mRNA vaccines has changed the way we can use biological information to provoke immunity. However, we must consider the actual clinical effectiveness of the platform rather than just how technological it is.

There are three main factors that will determine the success of an mRNA vaccine. Quality of antigen, efficient delivery and immune response. Even if an antigen has a strong theoretical immune relevance, if it is not efficiently expressed or presented this may result in disappointing results. Similarly, even if the RNA is very efficiently delivered it may not provide protection if it doesn't provoke an appropriate immune response.

The pandemic has shown that mRNA platforms can be rapidly developed for specific viruses. Further evidence can be seen from the RSV clinical programme and development of self-amplifying RNA products. However, developing vaccines for cancer is a different challenge. Therapeutic vaccines must overcome tumour heterogeneity, immune suppression and varying antigen expression.

The early studies into personalized cancer vaccines have shown that mRNA can provoke tumour specific T cell responses. However, we must ensure there is clinical benefit by performing adequately powered controlled trials. Whilst the flexibility of the platform is a huge benefit, we still need to know the biology of the disease, choose appropriate antigens, validate manufacturing and investigate in clinical trials to develop an effective vaccine. Future developments should focus on finding a balance between molecular innovation and clinical evidence.

14. Conclusion

The development of mRNA vaccines has introduced a new and important approach to vaccine development by temporarily producing specific antigens within the host cells. The clinical use of these vaccines during the pandemic has shown that synthetic RNA can provoke effective immune responses in humans when appropriate molecular engineering and delivery systems are used.

The development of modified nucleosides, optimized RNA design and lipid nano-particle formulations have helped overcome the initial challenges of using RNA for immunization.

Outside of the pandemic, this platform has shown promise in preventing respiratory disease, developing investigational vaccines for complex infectious diseases and personalized cancer immunotherapy.

However, there are still many challenges to overcome. RNA stability, delivery into cells, formulation toxicity, long term immune protection, cost of manufacturing and ensuring equitable access. Emerging technologies such as self-amplifying RNA, circular RNA, improved delivery materials and antigen design using computational methods may expand the applications of this technology. However, clinical benefit must be investigated using systematic pre-clinical research and appropriately designed clinical trials.

Overall, mRNA vaccines should be seen as a versatile and evolving platform in biomedicine. The future will depend on combining molecular biology, immunology, nanotechnology, pharmaceutical manufacturing and clinical medicine. Continued interdisciplinary research and international scientific collaboration will be essential to turn this potential into safe, effective and accessible medical interventions.

References

1. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. Direct gene transfer into mouse muscle in vivo. *Science*. 1990;247(4949):1465–1468. https://doi.org/10.1126/science.1690918

2. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. *Nature Reviews Drug Discovery*. 2014;13:759–780. https://doi.org/10.1038/nrd4278

3. Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. *Immunity*. 2005;23(2):165–175. https://doi.org/10.1016/j.immuni.2005.06.008

4. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. *Nature Reviews Drug Discovery*. 2018;17:261–279. https://doi.org/10.1038/nrd.2017.243

5. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *New England Journal of Medicine*. 2020;383:2603–2615. https://doi.org/10.1056/NEJMoa2034577

6. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *New England Journal of Medicine*. 2021;384:403–416. https://doi.org/10.1056/NEJMoa2035389

7. Metkar M, Pepin CS, Moore MJ. Tailor made: the art of therapeutic mRNA design. *Nature Reviews Drug Discovery*. 2024;23:67–83. https://doi.org/10.1038/s41573-023-00827-x

8. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. *Nature Reviews Materials*. 2021;6:1078–1094. https://doi.org/10.1038/s41578-021-00358-0

9. Cullis PR, Felgner PL. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. *Nature Reviews Drug Discovery*. 2024;23:709–722. https://doi.org/10.1038/s41573-024-00977-6

10. Pardi N, Krammer F. mRNA vaccines for infectious diseases—advances, challenges and opportunities. *Nature Reviews Drug Discovery*. 2024;23:838–861. https://doi.org/10.1038/s41573-024-01042-y

11. Mochida Y, Uchida S. mRNA vaccine designs for optimal adjuvanticity and delivery. *RNA Biology*. 2024;21(1):1–27. https://doi.org/10.1080/15476286.2024.2333123

12. Oda Y, Kumagai Y, Kanai M, et al. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial. *The Lancet Infectious Diseases*. 2024;24(4):351–360. https://doi.org/10.1016/S1473-3099(23)00650-3

13. Niu D, Wu Y, Lian J. Circular RNA vaccine in disease prevention and treatment. *Signal Transduction and Targeted Therapy*. 2023;8:341. https://doi.org/10.1038/s41392-023-01561-x

14. Wilson E, Goswami J, Baqui AH, et al. Efficacy and safety of an mRNA-based RSV preF vaccine in older adults. *New England Journal of Medicine*. 2023;389:2233–2244. https://doi.org/10.1056/NEJMoa2307079

15. Fatima M, Park PG, Hong KJ. Clinical advancements in mRNA vaccines against viral infections. *Clinical Immunology*. 2025;271:110424. https://doi.org/10.1016/j.clim.2024.110424

16. Ahmed S, Herschhorn A. mRNA-based HIV-1 vaccines. *Clinical Microbiology Reviews*. 2024. https://doi.org/10.1128/cmr.00041-24

17. Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. *Nature*. 2023;618:144–150. https://doi.org/10.1038/s41586-023-06063-y

18. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. *Nature*. 2025;639:1042–1051. https://doi.org/10.1038/s41586-024-08508-4

19. Bitounis D, Jacquinet E, Rogers MA, et al. Strategies to reduce the risks of mRNA drug and vaccine toxicity. *Nature Reviews Drug Discovery*. 2024;23:281–300. https://doi.org/10.1038/s41573-023-00859-3

20. Lu RM, Hsu HE, Perez SJLP, et al. Current landscape of mRNA technologies and delivery systems for new modality therapeutics. *Journal of Biomedical Science*. 2024;31:89. https://doi.org/10.1186/s12929-024-01080-z

21. Wang YS, Kumari M, Chen GH, et al. mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications. *Journal of Biomedical Science*. 2023;30:84. https://doi.org/10.1186/s12929-023-00977-5